VioQuest’s Xyfid is also intended to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions, by maintaining a moist wound and skin environment. If cleared by the FDA, Xyfid will be the company’s first commercial product.
Michael Becker, president and CEO of VioQuest, said: “The submission of our 510(k) application for Xyfid marks an important milestone in our company’s history and we look forward to reporting our progress on this and on other fronts in the months ahead.”